Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Directed Evolution of PD-L1-Targeted Affibodies by mRNA Display

25 May 2022

Abstract excerpt

Therapeutic monoclonal antibodies directed against PD-L1 (e.g., atezolizumab) disrupt PD-L1:PD-1 signaling and reactivate exhausted cytotoxic T-cells in the tumor compartment. Although anti-PD-L1 antibodies are successful as immune checkpoint inhibitor (ICI) therapeutics, there is still a pressing need to develop high-affinity, low-molecular-weight ligands for molecular imaging and diagnostic applications....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glycosylation and Glycoproteins Research
Share to Immunotherapy and Immune Responses
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35611948
DOI: 10.1021/acschembio.2c00218

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Directed Evolution of PD-L1-Targeted Affibodies by mRNA DisplayPMID 35611948Read ↗

De novo identification of tumor-specific internalizing human antibody–receptor pairs by phage-display methodsSemantic proximity Read ↗

Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging.Semantic proximity Read ↗

Advancements in mammalian display technology for therapeutic antibody development and beyond: current landscape, challenges, and future prospectsSemantic proximity Read ↗

NaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodiesSemantic proximity Read ↗

High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface AntigensSemantic proximity Read ↗

Cancer therapy via neoepitope-specific monoclonal antibody cocktailsSemantic proximity Read ↗

Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification.Semantic proximity Read ↗

Development of antibody-drug conjugates targeting L1CAM to treat metastatic cancerSemantic proximity Read ↗

Rapid discovery of high-affinity antibodies via massively parallel sequencing, ribosome display and affinity screeningSemantic proximity Read ↗

Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis.Semantic proximity Read ↗

Advancements in mRNA Encoded Antibodies for Passive ImmunotherapySemantic proximity Read ↗

In vitro nanobody discovery for integral membrane protein targetsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.